Competition.
Hypertension Diagnostics (HDII) makes an FDA-approved device that also non-invasively measures cardiovascular status (see profile below). A close examination of the CDIC device vs. the HDII CVProfilor indicates the two are not in direct competition. However, it also is clear that BioZ is not the only device of it kind on the market. While it may be tempting to dismiss HDII since the company is significantly earlier in development compared to CDIC (and it's stock performance is pathetic), and the company's earnings have been highly volatile (due to prior reliance on sales to the research market), the company is now focused entirely on marketing and selling it's clinical cardiovascular screening device.
And HDII is expected to earn $0.45 a share during its next FY (begins in July), which would be the first profitable year in the company's history. The company currently has 5 major research collaborations with drug companies, an arrangement that I suspect would also lead to the recommended use of the CVProfilor with the drugs emerging from the collaboration. HDII's CVProfilor has also been integral to countless publications (20+ in 2001 alone).
HDII and CDIC work in parallel universes. If you feel the non-invasive cardiovascular screening market describes a huge patient pool, where more than one player can achieve substantial revenues, then a closer examination of HDII is warranted.
Home page: hdi-pulsewave.com
(Disclosure: I own HDII and the HDIIW warrants)
================
Profile (Yahoo):
Hypertension Diagnostics, Inc. is engaged in the design, development, manufacture and marketing of proprietary medical devices that non-invasively detect subtle changes in the elasticity of both large and small arteries. The Company is currently marketing two versions of its product: the HDI/PulseWave CR-2000 Research CardioVascular Profiling System and the CVProfilor DO-2020 CardioVascular Profiling System. The Company also plans to market the CVProfilor MD-3000 CardioVascular Profiling System, previously referred to as the Model DO-2020i. The CR-2000 Research System, first promoted during December of 1998, is currently being marketed worldwide. It has a medical device CE Mark (CE 0123), which allows it to be marketed throughout the European Union, and it is being marketed for research purposes only in the United States, and not for screening, diagnosing or monitoring the treatment of patients. |
